1. Academic Validation
  2. Thyroxine treatments do not correct inner ear defects in tmprss1 mutant mice

Thyroxine treatments do not correct inner ear defects in tmprss1 mutant mice

  • Neuroreport. 2010 Sep 15;21(13):897-901. doi: 10.1097/WNR.0b013e32833dbd2d.
Syazana Hanifa 1 Hamish S Scott Pauline Crewther Michel Guipponi Justin Tan
Affiliations

Affiliation

  • 1 The Bionic Ear Institute, University of Melbourne, East Melbourne, Victoria, Australia.
Abstract

Complete deficiency of a member of the type II transmembrane serine protease family, tmprss1 (also known as hepsin), is associated with severe to profound hearing loss in mice and a gross enlargement of the tectorial membrane in the cochlea. Levels of thyroxine in these mice have been shown to be significantly lower when compared with wild-type controls. As thyroxine is critical for inner ear development, we delivered thyroxine to these mice during the prenatal or postnatal stage of development. Both the treatments could not ameliorate hearing loss or correct deformities in the tectorial membrane of these mutant mice, suggesting that a deficiency in tmprss1 affects thyroxine responsiveness in the inner ear in vivo.

Figures